These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 18413769)

  • 1. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
    Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
    Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abortive activation precedes functional deletion of CD8+ T cells following encounter with self-antigens expressed by resting B cells in vivo.
    Fraser JM; Janicki CN; Raveney BJ; Morgan DJ
    Immunology; 2006 Sep; 119(1):126-33. PubMed ID: 16796693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity.
    Morgan DJ; Kreuwel HT; Fleck S; Levitsky HI; Pardoll DM; Sherman LA
    J Immunol; 1998 Jan; 160(2):643-51. PubMed ID: 9551898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
    Marzo AL; Lake RA; Robinson BW; Scott B
    Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors.
    Hermans IF; Daish A; Yang J; Ritchie DS; Ronchese F
    Cancer Res; 1998 Sep; 58(17):3909-17. PubMed ID: 9731502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
    Gabrilovich DI; Ciernik IF; Carbone DP
    Cell Immunol; 1996 May; 170(1):101-10. PubMed ID: 8665590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
    VanOosten RL; Griffith TS
    Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis--implications for tumor tolerance.
    Robinson BW; Scott BM; Lake RA; Stumbles PA; Nelson DJ; Fisher S; Marzo AL
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):811s-817s. PubMed ID: 11300477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of CD8+CTL responses following gene gun immunization targeting the skin with intracutaneous injection of antigen-transduced dendritic cells.
    Gaffal E; Schweichel D; Tormo D; Steitz J; Lenz J; Basner-Tschakarjan E; Limmer A; Tüting T
    Eur J Cell Biol; 2007 Dec; 86(11-12):817-26. PubMed ID: 16928407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune-mediated intestinal inflammation-impact and regulation of antigen-specific CD8+ T cells.
    Westendorf AM; Fleissner D; Deppenmeier S; Gruber AD; Bruder D; Hansen W; Liblau R; Buer J
    Gastroenterology; 2006 Aug; 131(2):510-24. PubMed ID: 16890605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes to peptide structure, not concentration, contribute to expansion of the lowest avidity cytotoxic T lymphocytes.
    Leggatt GR; Narayan S; Fernando GJ; Frazer IH
    J Leukoc Biol; 2004 Oct; 76(4):787-95. PubMed ID: 15240746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
    Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
    J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
    Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
    J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor cell persistence and activation-induced unresponsiveness of peripheral CD8+ T cells.
    Ehl S; Barchet W; Oehen S; Aichele P; Hombach J; Hengartner H; Zinkernagel RM
    Eur J Immunol; 2000 Mar; 30(3):883-91. PubMed ID: 10741405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
    Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
    Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
    Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
    Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
    Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10.
    Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abdulsamad K; Adams SL
    Immunol Invest; 2008; 37(4):315-38. PubMed ID: 18569073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.